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Aim of the work: The aim was to assess the value of serum and pleural levels of cyfra 21-1 (frag-
ment of cytokeratin 19) and carcinoembryonic antigen (CEA) in the diagnosis of malignant pleural
effusion.
Patients and methods: This study was conducted on 48 patients divided into group I (benign effu-
sion) and group II (malignant effusion). Chest X-ray P.A view, pleural ﬂuid analysis and measure-
ment of serum and pleural levels of CEA and cyfra 21-1 were done.
Results: Serum and pleural levels of cyfra 21-1 and CEA were signiﬁcantly increased in the
malignant group and compared to other groups. Sensitivities of cyfra 21-1 and CEA in serum were
90.4 and 90.5 and in pleural ﬂuid were 94.7 and 92.6, the speciﬁcities of cyfra 21-1 and CEA in
serum were 86.9 and 83.5 and in pleural ﬂuid were 89.3 and 85.8 but sensitivity of both cyfra 21-
1 and CEA in serum and pleural ﬂuid was 100 and speciﬁcities in serum and pleural ﬂuid were
92.86 and 96.43.
Conclusion: Measurement of cyfra 21-1 and CEA in serum and pleural ﬂuid is helpful in differ-
entiation between benign and malignant pleural effusions.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Malignant pleural effusion is diagnosed by positive cytology
for malignant cells but pleural ﬂuid cytology is negative
in 50% of cases so, determination of tumor markers either inrculosis.
412 W.S. El-Shimy et al.serum or pleural ﬂuid has been used in the diagnosis of pleural
malignancy [1] (see Fig. 1).
Cyfra 21-1 is a fragment of cytokeratin (CK) 19 which is the
principal structural element of the cytoskeleton and expressed
in the pseudostratiﬁed epithelium lining the bronchial tree [2],
and been reported to be overexpressed in many lung cancer tis-
sue specimens [3] due to accelerated CK19 degradation as a
result of increased protease activity of caspase 3, a regulator
of the apoptosis cascade , leading to release of fragments into
the blood resulting in an increase of the cyfra 21-1 level in
serum and other body ﬂuids [4].
CEA is an oncofetal protein, elevates in the serum of
patients with colorectal, gastrointestinal, lung and breast carci-
nomas and also differentiates between benign and malignant
pleural effusions [5]. It is synthesized by malignant cells as
an adhesion molecule that is implicated in cell aggregation [6].
Aim of the work
To assess the diagnostic value of serum and pleural levels of
cyfra 21-1 and CEA in differentiation between benign and
malignant pleural effusion.
Patients and methods
This study was done in the Chest department – Tanta univer-
sity hospital and Tanta chest hospital during the period from
July 2013 to December 2013 and carried out on 48 patients
with pleural effusions divided into: Group I: included 28
patients with benign pleural effusion divided into 3 subgroups,
(A): included eight patients (four males and four females) with
parapneumonic pleural effusion, their mean age was
55.87 ± 11.420 years and characterized by the presence of
acute fever with purulent sputum, pulmonary inﬁltrate, leuko-
cytosis and neutrophilia with predominance of neutrophils in
cellular analysis of pleural ﬂuid [7], (B): included ten patients
(seven males and three Females) with tuberculous pleural effu-
sion, their mean age was 35.70 ± 8.97 years and diagnosed by
high positive tuberculin test, high ESR, lymphocytic pleural
effusion, positive acid fast bacilli in sputum or pleural ﬂuidROC Curve
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Figure 1 ROC curve of cyfra 21-1 sensitivityand pleural ﬂuid adenosine deaminase more than 40 u/l [8]
and (C): included ten patients (seven males and three females)
with transudative pleural effusion, their mean age was
56.60 ± 5.621 years and diagnosed according to Light’s crite-
ria by one of the following: – ratio of pleural ﬂuid lactate dehy-
drogenase (LDH) to that in serum was less than 0.6, ratio of
pleural ﬂuid total protein to that in plasma was less than 0.5
and the LDH level in the pleural ﬂuid needed to be less than
two thirds of the serum level [7]. All of them were cardiac
patients with congestive heart failure conﬁrmed by echocar-
diography. Group II: included twenty patients (ﬁfteen males
and ﬁve females) with malignant pleural effusion, their mean
age was 55.35 ± 8.13 years and diagnosed if pleural ﬂuid
cytology for malignant cells was positive [7].
Exclusion criteria:
 patients under chemo-therapy or radio-therapy,
 immuno-compromised patients,
 patients with bleeding tendency.
The following was done:
 full history taking and Complete clinical examination, chest
X-ray P.A view and CT if needed,
 Z. N stain of sputum and Tuberculin test (if TB was
suspected),
 complete blood picture, serum protein, LDH and ESR,
 pleural ﬂuid aspiration and analysis for [9]:
– Physical examination: color, odor, speciﬁc gravity and
aspect.
– Chemical examination including: protein level, LDH level,
total and differential cell count and adenosine deaminase
levels (when tuberculous effusion is suspected).
– Bacteriological examination.
– Cytological examination for malignant cells.
 Estimation of serum and pleural levels of carcinoembryonic
antigen used (CanAg CEA EIA-Ref: 401-10 Fujirebio
Diagnosting Inc., Elof Lindalvs gata 13, SE 414 58.
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and speciﬁcity in serum and pleural ﬂuid.
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Figure 2 ROC curve of CEA sensitivity and speciﬁcity in serum and pleural ﬂuid.
Tumour markers in pleural effusion 413Goteborg, Sweden) and cyfra 21-1 used (cyfra 21-1 EIA-
Ref: 211-10 Fujirebio Diagnosting Inc., Elof Lindalvs gata
13, SE 414 58 Goteborg, Sweden).
Statistical analysis
Statistics of this study was conducted using mean, standard
deviation, analysis of variance (ANOVA) test, sensitivity and
speciﬁcity by SPSS V.20.
Results
There was a signiﬁcant decrease of age (year) in the tubercu-
lous group compared with other groups, and there were no sig-
niﬁcant differences between parapneumonic, transudative and
malignant groups. There was a signiﬁcant decrease of serum to
pleural protein ratio in the transudative group compared to
other groups and the malignant group was signiﬁcantly
decreased compared to the other two groups and there was a
signiﬁcant increase in parapneumonic patients compared to
the tuberculous group. There was no signiﬁcant difference ofTable 1 Range, mean values, standard deviation and statistical anal
transudative and malignant pleural effusions.
Age Benign
Parapneumonic Tuberculous
Range 40–67 20–50
Mean 55.87 35.7
±SD 11.42 8.97
f Test 14.794
p Value <0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
0.001* 0.998 0.999pleural to serum LDH ratio between all groups. Pleural total
leukocytic count was signiﬁcantly higher in the tuberculous
group compared with other groups and it was signiﬁcantly
higher in the malignant group compared to both other groups
but, there was a signiﬁcant decrease in the transudative group
compared to the parapneumonic group. Serum and pleural
levels of cyfra 21-1and CEA were signiﬁcantly increased in
the malignant group compared to other groups but there were
no signiﬁcant differences between parapneumonic, tuberculous
and transudative groups. Sensitivities of cyfra 21-1 and CEA in
serum were 90.4 and 90.5 and in pleural ﬂuid were 94.7 and
92.6 respectively, the speciﬁcities of cyfra 21-1 and CEA in
serum were 86.9 and 83.5 respectively and in pleural ﬂuid were
89.3 and 85.8 respectively but sensitivity of both cyfra 21-1 and
CEA in serum and pleural ﬂuid was 100, speciﬁcities in serum
and pleural ﬂuid were 92.86 and 96.43 respectively (see Fig. 2
and Tables 1–3).
Discussion
In the present study the mean cyfra 21-1 and CEA levels in
serum and pleural ﬂuid were signiﬁcantly higher in malignantysis of ages (years) in patients with parapneumonic, tuberculous,
Malignant
Transudative
50–65 35–65
56.6 55.35
5.621 8.132
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.001* 0.001* 0.981
Table 3 Range, mean values, standard deviation and statistical analysis of pleural/serum LDH ratio in patients with parapneumonic,
tuberculous, transudative and malignant pleural effusions.
Pleural/serum LDH ratio Benign Malignant
Parapneumonic Tuberculous Transudative
Range 0.60–0.67 0.59–0.64 0.56–0.60 0.59–0.72
Mean 0.62 0.61 0.58 0.63
±SD 0.02 0.01 0.01 0.03
f Test 1.635
p Value 0.096
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.253 0.088 0.053 0.074 0.069 0.053
Table 2 Range, mean values, standard deviation and statistical analysis of pleural/serum protein ratio in patients with
parapneumonic, tuberculous, transudative and malignant pleural effusions.
Pleural/serum protein ratio Benign Malignant
Parapneumonic Tuberculous Transudative
Range 0.50–0.76 0.56–0.75 0.33–0.52 0.46–0.77
Mean 0.63 0.65 0.4 0.59
±SD 0.09 0.07 0.07 0.08
f Test 2.965
p Value 0.048*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.028* 0.019* 0.024* 0.041* 0.022* 0.030*
414 W.S. El-Shimy et al.pleural effusion than benign pleural effusion. Shitrit et al. con-
cluded that measurement of CEA levels in pleural effusions
yields the highest diagnostic accuracy but cyfra 21-1 could
serve as an alternative when the CEA assay is not available
[10]. Lee and Chang et al., concluded that the determination
of serum and pleural ﬂuid carcino-embryonic antigen and
cytokeratin 19 fragments in patients with effusions from pri-
mary lung cancer and in cases of suspicious malignant effusion
showing negative cytology, particularly in the absence of a visi-
ble tumor and/or unsuitability for invasive procedures may be
helpful as a complementary tool for the differential diagnosis
of pleural effusion [11]. Wagner et al. concluded that serum
and pleural ﬂuid levels of the cyfra 21-1, CEA, and CA15-3
are useful in differentiating between benign and malignant
pleural effusion [12]. Liu et al. concluded that the tumor mark-
ers detecting malignant effusion, caused by the SCLC, adeno-
carcinoma of lung, and lung squamous cell carcinoma, are
ProGRP, CEA and cyfra 21-1, respectively [13]. Gaspar
et al. concluded that measurement of CEA, CA 15.3 and
TAG 72 in pleural ﬂuid is a useful complementary test in the
differential diagnosis of pleural effusions of malignant origin
[14]. Radjenovic-Petkovic et al., studied the diagnostic value
of CEA in pleural ﬂuid for differential diagnosis of benign
and malignant pleural effusions .Their study was carried on
eighty-two patients with pleural effusion, forty-one with malig-
nant, and forty-one with non-malignant effusion and conclud-
ed that CEA may represent a helpful adjunct to cytology inorder to include malignancy as a probable diagnosis, thus
guiding the selection of patients for more invasive procedures
[15], Korczynski et al. found that the median pleural ﬂuid con-
centrations of the investigated tumor markers (CEA, cyfra 21-
1, and NSE) were signiﬁcantly higher in malignant exudates
compared with non-malignant effusions [16]. Hackbarth
et al., concluded that measurement of CEA in pleural ﬂuid
was signiﬁcantly higher in pleural ﬂuids of malignant effusions
compared to non-malignant effusions. In all cases, analysis of
CEA was superior to CA19-9 in identifying effusions of malig-
nant origin [17]. Huang et al., concluded that cyfra 21-1 is a
useful tumor marker for discriminating malignant effusion
due to lung adenocarcinoma from benign pleural effusion
and CEA has both the greatest sensitivity and speciﬁcity for
the diagnosis of patients with malignant pleural effusion [5].
Farag et al., concluded that cyfra 21-1 is a non-invasive reli-
able marker for differentiating malignant from benign pleural
effusions either it is used as a single marker or in combination
with CA15-3 so, negative cyfra 21-1 patients might not proceed
to unnecessary thoracoscopy [7]. Azimi et al., concluded that
cyfra 21-1 is helpful in diagnosing benign cases from malignant
cases [18] and Hsieh et al. found that cyfra 21-1, and CEA were
signiﬁcantly higher in lung adenocarcinoma-cytology negative
pleural effusion when compared with the benign one [19] (see
Table 4).
In the present study, a combination of cyfra 21-1 and CEA
in serum and pleural ﬂuid had higher sensitivity and accuracy
Table 4 Range, mean values, standard deviation and statistical analysis of total leukocytic count (TLC) in pleural ﬂuid (cell/mm3) in
patients with parapneumonic, tuberculous, transudative and malignant pleural effusions.
Total leukocytic count in pleural ﬂuid (cell/mm3) Benign Malignant
Parapneumonic Tuberculous Transudative
Range 1230–3111 1345–4560 126–1400 160–3600
Mean 2120.1 2430.5 421 1628.7
±SD 611.2 965 126.3 778.4
f Test 11.326
p Value 0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.001* 0.001* 0.001* 0.006* 0.001* 0.001*
Table 5 Range, mean values, standard deviation and statistical analysis of serum cyfra 21-1 (ng/ml) in patients with parapneumonic,
tuberculous, transudative and malignant pleural effusions.
Cyfra in serum Benign Malignant
Parapneumonic Tuberculous Transudative
Range 1.1–83 1.2–130 1.4–4.2 40–260
Mean 12.225 34.29 2.03 127.505
±SD 28.605 52.98 0.96 70.137
f Test 17.588
p Value 0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative vs malignant
0.818 0.977 0.001* 0.533 0.001* 0.001*
Tumour markers in pleural effusion 415than cyfra 21-1 or CEA alone. Lee and Chang found that the
combination of cyfra and CEA in serum and pleural ﬂuid had
a higher sensitivity and accuracy than each one alone [11].
Huang et al., found that cyfra 21-1 combined with CEA in
pleural ﬂuids increased diagnostic sensitivity to 66.7% in dif-
ferentiation of lung adenocarcinoma-associated cytologically
negative pleural effusions from benign ones when compared
with either cyfra 21-1 or CEA [5] (see Tables 5 and 6).
In the present study, serum cyfra 21-1 and CEA had nearly
the same sensitivity but cyfra 21-1 had a higher speciﬁcity andTable 6 Range, mean values, standard deviation and statistical
parapneumonic, tuberculous, transudative and malignant pleural eff
Cyfra in pleural ﬂuid Benign
Parapneumonic Tuberculous
Range 3.4–90 2–150
Mean 20.038 43.24
+SD 31.67 61.735
f Test 19.964
p Value 0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
0.827 0.936 0.001*accuracy than CEA. Pleural ﬂuid cyfra 21-1 had a higher sen-
sitivity, speciﬁcity and accuracy than CEA. Wagner et al.
found that serum cyfra 21-1 had a higher sensitivity than
CEA in differentiation between benign and malignant pleural
effusions [12], also Korczynski et al., found that serum cyfra
21-1 had a higher sensitivity and accuracy than CEA [16],
but Shitrit et al. found that CEA had a higher sensitivity, speci-
ﬁcity and accuracy than cyfra (21-1) because this study includ-
ed patients with lung adenocarcinoma and CEA is known to
be higher in these patients [10]. In the present study, thereanalysis of pleural ﬂuid cyfra 21-1 (ng/ml) in patients with
usions.
Malignant
Transudative
2.7–7.3 36.1–300
4.24 149.38
1.193 73.232
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative vs malignant
0.43 0.014* 0.002*
Table 7 Range, mean values, standard deviation and statistical analysis of serum CEA levels (lg/l) in patients with parapneumonic,
tuberculous, transudative and malignant groups.
CEA in serum Benign Malignant
Parapneumonic Tuberculous Transudative
Range 1–29 1–1.9 1–1.5 1–115
Mean 6.750 1.230 1.170 45.035
±SD 9.224 0.309 0.183 35.335
f Test 12.666
p Value 0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.960 0.959 0.002* 1.000 0.001* 0.002*
Table 8 Range, mean values, standard deviation and statistical analysis of pleural ﬂuid CEA levels (ug/l) in patients with
parapneumonic, tuberculous, transudative and malignant groups.
CEA in pleural ﬂuid Benign Malignant
Parapneumonic Tuberculous Transudative
Range 1.3–6.3 1–92 2.3–5.3 44–170
Mean 3.975 12.160 3.660 95.250
±SD 1.572 28.093 1.036 34.638
f Test 44.968
p Value 0.001*
Scheﬀe test
Parapneumonic
vs tuberculous
Parapneumonic
vs transudative
Parapneumonic
vs malignant
Tuberculous
vs transudative
Tuberculous
vs malignant
Transudative
vs malignant
0.911 1.000 0.001* 0.885 0.002* 0.001*
416 W.S. El-Shimy et al.was a signiﬁcant increase in cyfra 21-1 and CEA levels in pleu-
ral ﬂuid compared with serum in malignant pleural effusions.
Lee and Chang found that there was a signiﬁcant increase in
cyfra 21-1 levels in pleural ﬂuids compared with serum in
malignant pleural effusions, also there was a signiﬁcant
increase in CEA levels in pleural ﬂuids compared with serum
in malignant pleural effusions [11]. Wagner et al., and Biaoxue,
found that, the cyfra 21-1 and CEA levels were signiﬁcantly
higher in the pleural ﬂuid than in the serum in patients withTable 9 Cyfra 21-1(ng/ml) cutoff point, sensitivity, speciﬁcity, posi
Cyfra
Cutoﬀ Sensitivity Sp
Serum >4.2 90.4 86
Pleural ﬂuid >15 94.7 89
Table 10 CEA level (ug/l) cutoff point, sensitivity, speciﬁcity, posit
CEA
Cutoﬀ Sensitivity Sp
Serum >5.1 90.5 83
Pleural ﬂuid >6.3 92.6 85malignant pleural effusion [12,20] because of decreased lym-
phatic drainage caused by lymphatic obstruction due to pleural
invasion [21] so this study concluded that measurement of
cyfra 21-1 and CEA in serum and pleural ﬂuid is helpful in dif-
ferentiation between benign and malignant pleural effusions
but pleural ﬂuid cyfra 21-1 and CEA were more helpful than
those of serum. Cyfra 21-1 is more accurate than CEA in dif-
ferentiation between benign and malignant pleural effusions
but a combination of cyfra 21-1 and CEA in serum and pleuraltive and negative predictive value and accuracy.
eciﬁcity PPV NPV Accuracy
.9 87.4 91.4 88.6
.3 90.7 89.6 93.6
ive and negative predictive value and accuracy.
eciﬁcity PPV NPV Accuracy
.5 81.1 79.6 80.7
.8 89.8 84.6 90.4
Table 11 Sensitivity, speciﬁcity, positive and negative predic-
tive value and accuracy of combination of cyfra and CEA in
serum and pleural ﬂuid.
Sensitivity Speciﬁcity PPV NPV Accuracy
Cyfra 21-1+ CEA in serum
100 92.86 90.91 100.00 95.83
Cyfra 21-1+ CEA in pleural ﬂuid
100 96.43 95.24 100.00 97.92
Tumour markers in pleural effusion 417ﬂuid gives more accurate results than cyfra 21-1 or CEA alone
(see Tables 7–11).
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